The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

The Food and Drug Administration (FDA) has approved Abrysvo ® (respiratory syncytial virus [RSV] vaccine) for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

On Tuesday, the US Food and Drug Administration (FDA) approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for people 18 to 59 who are more vulnerable to the virus. Pfizer’s vaccine ...

The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two ...